Precigen (PGEN) Stock Overview
A discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
PGEN Community Fair Values
Create NarrativeSee what 41 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Precigen, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.86 |
| 52 Week High | US$5.95 |
| 52 Week Low | US$1.40 |
| Beta | 1.06 |
| 1 Month Change | 35.02% |
| 3 Month Change | 80.31% |
| 1 Year Change | 312.68% |
| 3 Year Change | 409.57% |
| 5 Year Change | -8.72% |
| Change since IPO | -76.30% |
Recent News & Updates
Precigen: Entering The Oncology 'Sweet Spot'
Summary Precigen earns a STRONG BUY rating following the commercial success of PAPZIMEOS and rapid revenue growth. PGEN's AdenoVerse platform underpins a validated, scalable franchise, with PAPZIMEOS now endorsed as first-line therapy for RRP and covered by major US insurers. Management projects cash flow breakeven in 2026, with Wall Street revising EPS and revenue estimates sharply since the 1Q earnings call. Risks include competitive threats from INO-3107, but PGEN's commercial momentum remains strong. Read the full article on Seeking Alpha
PGEN: Orphan Exclusivity And Durable RRP Data Will Drive Future Upside
Analysts have raised their fair value estimate for Precigen from $8.50 to $12.45, citing higher price targets tied to Papzimeo’s orphan-drug exclusivity, stronger-than-guided launch traction, and updated assumptions for the discount rate, revenue growth, profit margin, and future P/E. Analyst Commentary Recent Street research around Precigen has focused on the implications of Papzimeo’s launch performance and the orphan-drug exclusivity decision, with several price targets adjusted to reflect these updates.Precigen (PGEN) Stock Could Be 79% Undervalued After FDA Exclusivity Win
Precigen (PGEN) is back in focus after the FDA granted orphan drug exclusivity to PAPZIMEOS for adult recurrent respiratory papillomatosis, limiting similar competing therapies for seven years and defining a clearer commercial runway. See our latest analysis for Precigen. The FDA decision comes after a period of strong momentum for Precigen, with the share price delivering a 46.95% 3 month share price return and a very large 1 year total shareholder return. However, the 5 year total...Recent updates
Precigen: Entering The Oncology 'Sweet Spot'
Summary Precigen earns a STRONG BUY rating following the commercial success of PAPZIMEOS and rapid revenue growth. PGEN's AdenoVerse platform underpins a validated, scalable franchise, with PAPZIMEOS now endorsed as first-line therapy for RRP and covered by major US insurers. Management projects cash flow breakeven in 2026, with Wall Street revising EPS and revenue estimates sharply since the 1Q earnings call. Risks include competitive threats from INO-3107, but PGEN's commercial momentum remains strong. Read the full article on Seeking AlphaPGEN: Orphan Exclusivity And Durable RRP Data Will Drive Future Upside
Analysts have raised their fair value estimate for Precigen from $8.50 to $12.45, citing higher price targets tied to Papzimeo’s orphan-drug exclusivity, stronger-than-guided launch traction, and updated assumptions for the discount rate, revenue growth, profit margin, and future P/E. Analyst Commentary Recent Street research around Precigen has focused on the implications of Papzimeo’s launch performance and the orphan-drug exclusivity decision, with several price targets adjusted to reflect these updates.Precigen (PGEN) Stock Could Be 79% Undervalued After FDA Exclusivity Win
Precigen (PGEN) is back in focus after the FDA granted orphan drug exclusivity to PAPZIMEOS for adult recurrent respiratory papillomatosis, limiting similar competing therapies for seven years and defining a clearer commercial runway. See our latest analysis for Precigen. The FDA decision comes after a period of strong momentum for Precigen, with the share price delivering a 46.95% 3 month share price return and a very large 1 year total shareholder return. However, the 5 year total...Precigen: UltraCAR-T Development Brings Another Side Of Pipeline Advancement
Summary BLA of PRGN-2012 for patients with Recurrent Respiratory Papillomatosis was accepted by FDA with a Priority Review date of August 27th of 2025. Marketing approval of PRGN-2012 for RRP would be huge because there is no FDA approved drugs for RRP. Also, there are an estimated 27,000 people in the United States who have it. PGEN is looking to form a strategic partnership or collaboration agreement to advance its UltraCAR-Ts. This technology is crucial because it could change CAR-T landscape for the better. PRGN-3006 is an UltraCAR-T being developed to target patients with Acute Myeloid Leukemia; PRGN-3008 is an UltraCAR-T targeting patients with CD19 solid tumors and autoimmune disorders. Read the full article on Seeking AlphaPrecigen: Successful Proof Of Platform, But Cash Worries Remain
Summary Precigen's lead asset, PRGN-2012, shows promising results in treating Recurrent Respiratory Papillomatosis, achieving a 51% complete response rate and reducing surgical interventions. Financially, Precigen has a market cap of $468mn and a cash runway into 2026, but needs more funds for commercialization. The company is prioritizing PRGN-2012's development, restructuring operations, and cutting 20% of its workforce to extend its cash runway. Despite financial risks, Precigen's proven platforms and promising data make it a potential worthwhile investment, pending resolution of cash issues. Read the full article on Seeking AlphaWe're Keeping An Eye On Precigen's (NASDAQ:PGEN) Cash Burn Rate
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Precigen: RRP Targeting With AdenoVerse Technology Platform
Summary FDA agreed to allow phase 1/2 study to serve as the basis for being able to file for Accelerated Approval of PRGN-2012 for the treatment of patients with recurrent respiratory papillomatosis. A BLA filing of PRGN-2012 for the treatment of patients with recurrent respiratory papillomatosis is expected in the 2nd half of 2024. It is projected that it could earn $2 billion in peak sales globally of PRGN-2012 for the treatment of patients with recurrent respiratory papillomatosis. PRGN-2009 which also uses the AdenoVerse technology has one phase 2 study targeting OPSCC underway and another one targeting recurrent/metastatic cervical cancer patients expected to begin in 2024. Read the full article on Seeking AlphaWill Precigen (NASDAQ:PGEN) Spend Its Cash Wisely?
We can readily understand why investors are attracted to unprofitable companies. For example, although...Is Precigen (NASDAQ:PGEN) Using Debt In A Risky Way?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...Shareholder Returns
| PGEN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 21.6% | 7.5% | -2.5% |
| 1Y | 312.7% | 40.9% | 19.0% |
Return vs Industry: PGEN exceeded the US Biotechs industry which returned 40.9% over the past year.
Return vs Market: PGEN exceeded the US Market which returned 19% over the past year.
Price Volatility
| PGEN volatility | |
|---|---|
| PGEN Average Weekly Movement | 11.5% |
| Biotechs Industry Average Movement | 10.5% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: PGEN's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: PGEN's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 160 | Helen Sabzevari | precigen.com |
Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1/1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors.
Precigen, Inc. Fundamentals Summary
| PGEN fundamental statistics | |
|---|---|
| Market cap | US$2.09b |
| Earnings (TTM) | -US$383.42m |
| Revenue (TTM) | US$31.60m |
Is PGEN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PGEN income statement (TTM) | |
|---|---|
| Revenue | US$31.60m |
| Cost of Revenue | US$42.78m |
| Gross Profit | -US$11.18m |
| Other Expenses | US$372.24m |
| Earnings | -US$383.42m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.08 |
| Gross Margin | -35.39% |
| Net Profit Margin | -1,213.54% |
| Debt/Equity Ratio | 462.2% |
How did PGEN perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/28 02:35 |
| End of Day Share Price | 2026/06/26 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Precigen, Inc. is covered by 10 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ying Huang | Barclays |
| Derik de Bruin | BofA Global Research |
| Justin Walsh | B. Riley Securities, Inc. |